Arby2000- right on! The blocked posters outnumber the unblocked for me for the last 2 weeks maybe longer. What are they afraid of? I don’t think they know. But, if they or anyone cares to revisit managements discussion pages 23/24 of the 10K, they’d know what they’re afraid of.
Flaskworks and Eden’s are going to 12x legacy methods, is being monetized for autologous applications, and as such is exactly what the 10K describes- MAJOR.
They’d learn there’s a deal expectation after inspections and regulator questions but before MHRA approval.
They’d learn about what in licensing means and how that would manifest in cross licensing agreements with BP.
They’d learn how Sawston would be built out with additional class C cleanrooms and how there’s a dedicated lab for next gen Eden’s.
They’d learn about vast foundational patent protection on Eden’s.
They’d learn that nwbo has figured out how to make L even more powerful.
They’d learn there are collaborations coming for trials that involve in licensing and stand alone.
They’d learn how very valuable the compassionate use program will support additional RA applications using RWE and Proteomics.
They’d learn Direct is coming.
To sum it up, this investment is way way beyond GBM in the UK !!!
News 
Market Data 
Discover 
AI
